Identification of First-in-Class KAT6A Degraders Leading to Potent & KAT6A-Selective Oral Development Candidate PRT13722

• Discovery of KAT6A degrader compounds
• Characterization and proof-of-concept studies with KAT6A degraders
• Preclinical profile of KAT6A-selective development candidate PRT13722

Speakers:

Andrew Buesking

Sr. Director

Prelude Therapeutics​